Navigation Links
Healthpoint Launches New Corporate Identity
Date:2/23/2011

FORT WORTH, Texas, Feb. 23, 2011 /PRNewswire/ -- Healthpoint today announced the launch of a new corporate identity featuring a new company name, Healthpoint Biotherapeutics, along with an updated brandmark and corporate tagline, "The Science of Healing™". Together, the new corporate identity is designed to communicate the company's commitment to scientific innovations in tissue repair and healing that will ultimately contribute to improved outcomes and quality of life for the patients it serves.

"For two decades, Healthpoint has been a trusted name in the wound care community," said Travis Baugh, President and Chief Operating Officer of Healthpoint Biotherapeutics. "We sought to acknowledge this heritage while updating our identity to better reflect our future direction where an increasing understanding of wound biology is driving the development of new biopharmaceuticals designed to stimulate the body's own regenerative processes to close and heal wounds more efficiently and more rapidly."

Healthpoint Biotherapeutics' diversified product portfolio currently serves large and growing markets that continue to expand given current demographic and epidemiological trends. The company is well positioned to benefit from this market growth with its specialized sales force, strong performance of best-in-class products, award winning educational resources and future prospects borne of a strategically directed pipeline.

About Chronic Wounds and BurnsMost wounds proceed toward healing in a timely, organized manner; however, for many wounds the healing process is slowed, less well organized and may even come to a halt altogether, leading to a chronic wound (one that appears stuck in a prolonged, non-healing, inflammatory state). Chronic wounds are often derivative of another illness or condition such as diabetes, obesity, peripheral vascular disease and immobility. These wounds–including diabetic, venous, arterial and pressure ulcers–are considered inherently difficult-to-heal and at risk of becoming chronic due to the underlying disease state or condition of the individual interfering with the normal healing process. Millions of people currently suffer from these types of wounds, and many more are likely to be affected in the future as the prevalence of the underlying disease states and conditions continues to rise.

An estimated $5-7 billion is spent each year on the treatment of chronic wounds in the United States alone, and these costs are increasing at annual rate of 7-10%. Despite these expenditures and clinical efforts, many of these wounds fail to heal in a timely manner, increasing the risk of many undesirable consequences and complications such as local infection (including cellulitis and abscesses), bacteremia and sepsis, pain, osteomyelitis, dermatitis, possible malignancy, amputation and even death. The longer it takes for a wound to heal, the greater the likelihood of complications.

"The factors that cause wounds to fail to heal are not well understood," said Bert Slade, MD, Chief Medical Officer of Healthpoint Biotherapeutics. "However, the science is evolving rapidly and suggests new biopharmaceutical technologies will be the next stage of innovation in turning the sometimes elusive process of healing into a dependable reality."

The incidence of burns requiring treatment is estimated at 500,000 per year in the United States. Most are treated on an outpatient basis, but approximately 40,000 are hospitalized for treatment (including 25,000 admissions to specialized burn centers) at a cost of approximately $200,000 per patient. Many of these wounds are treated with clinical algorithms similar to those applied to difficult-to-heal and chronic wounds.

About Healthpoint BiotherapeuticsHealthpoint Biotherapeutics is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, cost-effective solutions for tissue repair and healing. The company's diversified research and development strategy is presently centered around therapeutic enzymes, biologics and next-generation cell- and cell-matrix based therapies for the prevention and treatment of acute, chronic and burn-related wounds. Healthpoint Biotherapeutics is also committed to advancing the care and treatment of wounds through support of industry leading continuing education from THE WOUND INSTITUTE®. To learn more about this comprehensive and award winning educational resource, please visit TheWoundInstitute.com. Healthpoint Biotherapeutics is a DFB Pharmaceuticals, Inc., affiliate company, and is based in Fort Worth, Texas. For more information, visit the company website at www.Healthpoint.com.

Healthpoint Biotherapeutics and design, The Science of Healing, THE WOUND INSTITUTE and THEWOUNDINSTITUTE.COM are registered trademarks of Healthpoint, Ltd.Contact: Robert BancroftExecutive Vice President, Strategic and Commercial Developmentrob.bancroft@healthpoint.com1.800.441.8227
'/>"/>

SOURCE Healthpoint Biotherapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Healthpoint to Present at 29th Annual J.P. Morgan Healthcare Conference
2. Healthpoint Launches Collagenase SANTYL(R) Ointment in Canada
3. HEALTHPOINT-Sponsored Venous Leg Ulcer Clinical Trial Enrolls First Subject for Second Phase II Study
4. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
5. Healthpoint Initiates Randomized, Double-Blind Study to Evaluate Effectiveness of Collagenase SANTYL(R) Ointment on Wound Healing
6. New Mexico Software Launches Companys First International Telemedicine Service
7. Onset Dermatologics Launches HylatopicPlus-Aurstat™ Kit
8. ResearchDx Launches Contract Diagnostics Organization (CDO)
9. PreXion Launches New Faster, Lower Radiation PreXion3D Elite Cone Beam Imaging System
10. Zimmer Launches PathFinder NXT™ Minimally Invasive Pedicle Screw System
11. Success Factors and Failure Points in Biopharmaceutical Product Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... On February 22, 2017 the U.S. Department ... withdraw previous guidance issued by the Obama Administration requiring schools to treat transgender ... by the Obama Administration came in response to a growing number of states ...
(Date:2/23/2017)... ... 2017 , ... Rare Disease Report®, which is the only ... Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on February ... e-newsletter and quarterly publication, will be conducting interviews with patients and advocates in ...
(Date:2/23/2017)... North Hollywood, CA (PRWEB) , ... February 23, 2017 , ... ... are pleased to announce that they are sponsoring a raffle. Throughout the month of ... drawing. Winners will receive a gift card for a dinner for two at the ...
(Date:2/23/2017)... ... February 23, 2017 , ... On ... a diverse symposium on “Doping in Sport: How the Culture Might Change,” ... & Hampton LLP. The symposium will be held at Pepperdine University in Malibu, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data ... that Premier Research, a leading clinical development service provider, has selected ERT’s Trial ... complex, due in part to an array of circumstances including the use of ...
Breaking Medicine News(10 mins):